SMO (SMOOTHENED TRANSMEMBRANE PROTEIN) INHIBITORS (VISMODEGIB) IN TREATMENT OF BASAL CELL CARCINOMA (BCC) OF OCULAR ADNEXA

Abstract

Basal Cell Carcinoma (BCC) is one of the well spread malignant skin cancers. Eighty percent of it occurs in the head-neck area of which 20% in the eyelids. The major genes for BCC are: PTCH1 and PTCH2. PTCH1 supresses transmembrane Smoothened (SMO) protein, while PTCH2 have his role uncleared, but there are evidences for involvement in Hedgehog signalling pathway. From all cases of BCC of adnexa, advanced BCC represents a small percentage of 1-10%. Advanced BCC has his two forms of metastatic mBCC and local advanced laBCC. The surgical approach is a mainstay in the treatment of BCC. Some cases the anatomical and functional results are expected to be poor, due to difficult location of the tumour, such patients with laBCC and mBCC can benefit from medical treatment together with surgery and radiotherapy or alone. Systemic treatment, as of Vismodegib is a good candidate for these patients with mild to moderate side effect’s profile.

Keywords

• basal cell carcinoma
• eyelid
• oncology
• vismodegib
• ophthalmology
• free cutaneous graft